| Year |
Citation |
Score |
| 2021 |
Star E, Stevens M, Gooding C, Smith CWJ, Li L, Ayine ML, Harper SJ, Bates DO, Oltean S. A drug-repositioning screen using splicing-sensitive fluorescent reporters identifies novel modulators of VEGF-A splicing with anti-angiogenic properties. Oncogenesis. 10: 36. PMID 33941763 DOI: 10.1038/s41389-021-00323-0 |
0.346 |
|
| 2021 |
Uzor S, Porazinski SR, Li L, Clark B, Ajiro M, Iida K, Hagiwara M, Alqasem AA, Perks CM, Wilson ID, Oltean S, Ladomery MR. CDC2-like (CLK) protein kinase inhibition as a novel targeted therapeutic strategy in prostate cancer. Scientific Reports. 11: 7963. PMID 33846420 DOI: 10.1038/s41598-021-86908-6 |
0.309 |
|
| 2020 |
Li L, Hobson L, Perry L, Clark B, Heavey S, Haider A, Sridhar A, Shaw G, Kelly J, Freeman A, Wilson I, Whitaker H, Nurmemmedov E, Oltean S, Porazinski S, et al. Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer. British Journal of Cancer. PMID 32581342 DOI: 10.1038/S41416-020-0951-2 |
0.364 |
|
| 2019 |
Kitchen P, Lee KY, Clark D, Lau N, Lertsuwan J, Sawasdichai A, Satayavivad J, Oltean S, Afford S, Gaston K, Jayaraman PS. A runaway PRH/HHEX-Notch3 positive feedback loop drives cholangiocarcinoma and determines response to CDK4/6 inhibition. Cancer Research. PMID 31843982 DOI: 10.1158/0008-5472.Can-19-0942 |
0.349 |
|
| 2019 |
Stevens M, Oltean S. Modulation of the Apoptosis Gene Bcl-x Function Through Alternative Splicing. Frontiers in Genetics. 10: 804. PMID 31552099 DOI: 10.3389/Fgene.2019.00804 |
0.338 |
|
| 2019 |
Munkley J, Ling L, Krishnan SRG, Hysenaj G, Scott E, Dalgliesh C, Oo HZ, Maia TM, Cheung K, Ehrmann I, Livermore KE, Zielinska H, Thompson O, Knight B, McCullagh P, ... ... Oltean S, et al. Androgen-regulated transcription of drives alternative splicing patterns in prostate cancer. Elife. 8. PMID 31478829 DOI: 10.7554/Elife.47678 |
0.382 |
|
| 2019 |
Stevens M, Star E, Lee M, Innes E, Li L, Bowler E, Harper S, Bates DO, Oltean S. The VEGF-A exon 8 splicing-sensitive fluorescent reporter mouse is a novel tool to assess the effects of splicing regulatory compounds . Rna Biology. 1-10. PMID 31432737 DOI: 10.1080/15476286.2019.1652522 |
0.433 |
|
| 2019 |
Melegh Z, Oltean S. Targeting Angiogenesis in Prostate Cancer. International Journal of Molecular Sciences. 20. PMID 31151317 DOI: 10.3390/Ijms20112676 |
0.396 |
|
| 2019 |
Bowler E, Oltean S. Alternative Splicing in Angiogenesis. International Journal of Molecular Sciences. 20. PMID 31027366 DOI: 10.3390/Ijms20092067 |
0.378 |
|
| 2019 |
Stevens M, Oltean S. Modulation of Receptor Tyrosine Kinase Activity through Alternative Splicing of Ligands and Receptors in the VEGF-A/VEGFR Axis. Cells. 8. PMID 30925751 DOI: 10.3390/Cells8040288 |
0.434 |
|
| 2019 |
Stevens M, Neal CR, Craciun EC, Dronca M, Harper SJ, Oltean S. The natural drug DIAVIT is protective in a type II mouse model of diabetic nephropathy. Plos One. 14: e0212910. PMID 30865689 DOI: 10.1371/Journal.Pone.0212910 |
0.385 |
|
| 2019 |
Kikuchi R, Stevens M, Harada K, Oltean S, Murohara T. Anti-angiogenic isoform of vascular endothelial growth factor-A in cardiovascular and renal disease. Advances in Clinical Chemistry. 88: 1-33. PMID 30612603 DOI: 10.1016/Bs.Acc.2018.10.001 |
0.418 |
|
| 2019 |
Munkley J, Li L, Krishnan SRG, Hysenaj G, Scott E, Dalgliesh C, Oo HZ, Maia TM, Cheung K, Ehrmann I, Livermore KE, Zielinska H, Thompson O, Knight B, McCullagh P, ... ... Oltean S, et al. Author response: Androgen-regulated transcription of ESRP2 drives alternative splicing patterns in prostate cancer Elife. DOI: 10.7554/Elife.47678.028 |
0.346 |
|
| 2018 |
Jumbe SL, Porazinski SR, Oltean S, Mansell JP, Vahabi B, Wilson ID, Ladomery MR. The Evolutionarily Conserved Cassette Exon 7b Drives ERG's Oncogenic Properties. Translational Oncology. 12: 134-142. PMID 30296658 DOI: 10.1016/J.Tranon.2018.09.001 |
0.403 |
|
| 2018 |
Bates DO, Beazley-Long N, Benest AV, Ye X, Ved N, Hulse RP, Barratt S, Machado MJ, Donaldson LF, Harper SJ, Peiris-Pages M, Tortonese DJ, Oltean S, Foster RR. Physiological Role of Vascular Endothelial Growth Factors as Homeostatic Regulators. Comprehensive Physiology. 8: 955-979. PMID 29978898 DOI: 10.1002/Cphy.C170015 |
0.433 |
|
| 2018 |
Stevens M, Oltean S. Modulation of VEGF-A Alternative Splicing as a Novel Treatment in Chronic Kidney Disease. Genes. 9. PMID 29462869 DOI: 10.3390/Genes9020098 |
0.455 |
|
| 2018 |
Stevens M, Neal CR, Salmon AHJ, Bates DO, Harper SJ, Oltean S. Vascular Endothelial Growth Factor-A165b Restores Normal Glomerular Water Permeability in a Diphtheria-Toxin Mouse Model of Glomerular Injury. Nephron. PMID 29393270 DOI: 10.1159/000485664 |
0.418 |
|
| 2017 |
Barratt SL, Blythe T, Jarrett C, Ourradi K, Shelley-Fraser G, Day MJ, Qiu Y, Harper S, Maher TM, Oltean S, Hames TJ, Scotton CJ, Welsh GI, Bates DO, Millar AB. Differential Expression of VEGF-Axxx Isoforms is Critical for Development of Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. PMID 28661183 DOI: 10.1164/Rccm.201603-0568Oc |
0.397 |
|
| 2017 |
Kollareddy M, Sherrard A, Park JH, Szemes M, Gallacher K, Melegh Z, Oltean S, Michaelis M, Cinatl J, Kaidi A, Malik K. The small molecule inhibitor YK-4-279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosis. Cancer Letters. PMID 28602975 DOI: 10.1016/J.Canlet.2017.05.027 |
0.337 |
|
| 2017 |
Stevens M, Neal CR, Salmon AH, Bates DO, Harper SJ, Oltean S. VEGF-A165 b protects against proteinuria in a mouse model with progressive depletion of all endogenous VEGF-A splice isoforms from the kidney. The Journal of Physiology. PMID 28574576 DOI: 10.1113/Jp274481 |
0.426 |
|
| 2017 |
Bates DO, Morris JC, Oltean S, Donaldson LF. Pharmacology of Modulators of Alternative Splicing. Pharmacological Reviews. 69: 63-79. PMID 28034912 DOI: 10.1124/Pr.115.011239 |
0.35 |
|
| 2016 |
Bullock N, Oltean S. The many faces of SRPK1. The Journal of Pathology. PMID 27859253 DOI: 10.1002/Path.4846 |
0.373 |
|
| 2016 |
Mavrou A, Oltean S. SRPK1 inhibition in prostate cancer: a novel anti-angiogenic treatment through modulation of VEGF alternative splicing. Pharmacological Research. PMID 26995304 DOI: 10.1016/J.Phrs.2016.03.013 |
0.423 |
|
| 2016 |
Stevens M, Oltean S. Alternative Splicing in CKD. Journal of the American Society of Nephrology : Jasn. PMID 26763787 DOI: 10.1681/Asn.2015080908 |
0.367 |
|
| 2016 |
Stevens M, Oltean S, Harper S. Manipulation of VEGF-A splicing using natural compounds as a potential therapeutic in diabetic nephropathy Journal of the International Society of Antioxidants in Nutrition & Health. 3. DOI: 10.18143/Jisanh_V3I4_1313 |
0.395 |
|
| 2015 |
Bullock N, Potts J, Simpkin AJ, Koupparis A, Harper SJ, Oxley J, Oltean S. Serine-arginine protein kinase 1 (SRPK1), a determinant of angiogenesis, is upregulated in prostate cancer and correlates with disease stage and invasion. Journal of Clinical Pathology. PMID 26500332 DOI: 10.1136/Jclinpath-2015-203125 |
0.417 |
|
| 2015 |
Oltean S. Modulators of alternative splicing as novel therapeutics in cancer. World Journal of Clinical Oncology. 6: 92-5. PMID 26468443 DOI: 10.5306/Wjco.V6.I5.92 |
0.411 |
|
| 2015 |
Munkley J, Oltean S, Vodák D, Wilson BT, Livermore KE, Zhou Y, Star E, Floros VI, Johannessen B, Knight B, McCullagh P, McGrath J, Crundwell M, Skotheim RI, Robson CN, et al. The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer. Oncotarget. PMID 26452038 DOI: 10.18632/Oncotarget.6024 |
0.362 |
|
| 2015 |
Bunni J, Shelley-Fraser G, Stevenson K, Oltean S, Salmon A, Harper SJ, Carter JG, Bates DO. Circulating levels of anti-angiogenic VEGF-A isoform (VEGF-Axxxb) in colorectal cancer patients predicts tumour VEGF-A ratios. American Journal of Cancer Research. 5: 2083-9. PMID 26269767 |
0.309 |
|
| 2015 |
Hamdollah Zadeh MA, Amin EM, Hoareau-Aveilla C, Domingo E, Symonds KE, Ye X, Heesom KJ, Salmon A, D'Silva O, Betteridge KB, Williams AC, Kerr DJ, Salmon AH, Oltean S, Midgley RS, et al. Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance. Molecular Oncology. 9: 167-78. PMID 25224594 DOI: 10.1016/J.Molonc.2014.07.017 |
0.455 |
|
| 2015 |
Batson J, Oltean S, Bates D. Targeting the angiogenic 'splice' switch; inhibition of SRPK1 as a novel therapeutic approach in prostate cancer Cancer Cell & Microenvironment. 2. DOI: 10.14800/Ccm.876 |
0.488 |
|
| 2015 |
Star E, Harper S, Bates D, Oltean S. Abstract A14: Use of VEGF-based splicing-sensitive fluorescent reporters to screen for anti-angiogenic molecules Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Tumang15-A14 |
0.439 |
|
| 2014 |
Oltean S, Qiu Y, Ferguson JK, Stevens M, Neal C, Russell A, Kaura A, Arkill KP, Harris K, Symonds C, Lacey K, Wijeyaratne L, Gammons M, Wylie E, Hulse RP, et al. Vascular Endothelial Growth Factor-A165b Is Protective and Restores Endothelial Glycocalyx in Diabetic Nephropathy. Journal of the American Society of Nephrology : Jasn. PMID 25542969 DOI: 10.1681/Asn.2014040350 |
0.371 |
|
| 2014 |
Mavrou A, Brakspear K, Hamdollah-Zadeh M, Damodaran G, Babaei-Jadidi R, Oxley J, Gillatt DA, Ladomery MR, Harper SJ, Bates DO, Oltean S. Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer. Oncogene. PMID 25381816 DOI: 10.1038/Onc.2014.360 |
0.479 |
|
| 2014 |
Gammons MV, Lucas R, Dean R, Coupland SE, Oltean S, Bates DO. Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma. British Journal of Cancer. 111: 477-85. PMID 25010863 DOI: 10.1038/Bjc.2014.342 |
0.419 |
|
| 2014 |
Mavrou A, Bates D, Oltean S. Abstract 2749: SRPK1 inhibition and modulation of VEGF alternative splicing as a potential therapeutic strategy in prostate cancer Cancer Research. 74: 2749-2749. DOI: 10.1158/1538-7445.Am2014-2749 |
0.451 |
|
| 2013 |
Bates DO, Mavrou A, Qiu Y, Carter JG, Hamdollah-Zadeh M, Barratt S, Gammons MV, Millar AB, Salmon AH, Oltean S, Harper SJ. Detection of VEGF-A(xxx)b isoforms in human tissues. Plos One. 8: e68399. PMID 23935865 DOI: 10.1371/Journal.Pone.0068399 |
0.435 |
|
| 2013 |
Mavrou A, Oltean S, Bates D. Abstract 380: Serine-Arginine protein kinase 1 (SRPK1) - A potential target of angiogenesis in prostate cancer. Cancer Research. 73: 380-380. DOI: 10.1158/1538-7445.Am2013-380 |
0.47 |
|
| 2013 |
Oltean S, Bates DO. Hallmarks of alternative splicing in cancer Oncogene. DOI: 10.1038/Onc.2013.533 |
0.416 |
|
| 2012 |
Oltean S, Gammons M, Hulse R, Hamdollah-Zadeh M, Mavrou A, Donaldson L, Salmon AH, Harper SJ, Ladomery MR, Bates DO. SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases. Biochemical Society Transactions. 40: 831-5. PMID 22817743 DOI: 10.1042/Bst20120051 |
0.454 |
|
| 2012 |
Oltean S, Neal CR, Mavrou A, Patel P, Ahad T, Alsop C, Lee T, Sison K, Qiu Y, Harper SJ, Bates DO, Salmon AH. VEGF165b overexpression restores normal glomerular water permeability in VEGF164-overexpressing adult mice. American Journal of Physiology. Renal Physiology. 303: F1026-36. PMID 22811490 DOI: 10.1152/Ajprenal.00410.2011 |
0.415 |
|
| 2011 |
Amin EM, Oltean S, Hua J, Gammons MV, Hamdollah-Zadeh M, Welsh GI, Cheung MK, Ni L, Kase S, Rennel ES, Symonds KE, Nowak DG, Royer-Pokora B, Saleem MA, Hagiwara M, et al. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell. 20: 768-80. PMID 22172722 DOI: 10.1016/J.Ccr.2011.10.016 |
0.449 |
|
| 2011 |
Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, Herold CI, Marcom PK, George DJ, Garcia-Blanco MA. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Molecular Cancer Research : McR. 9: 997-1007. PMID 21665936 DOI: 10.1158/1541-7786.Mcr-10-0490 |
0.323 |
|
| 2010 |
Qiu Y, Ferguson J, Oltean S, Neal CR, Kaura A, Bevan H, Wood E, Sage LM, Lanati S, Nowak DG, Salmon AH, Bates D, Harper SJ. Overexpression of VEGF165b in podocytes reduces glomerular permeability. Journal of the American Society of Nephrology : Jasn. 21: 1498-509. PMID 20688932 DOI: 10.1681/Asn.2009060617 |
0.428 |
|
| 2009 |
Qiu Y, Hoareau-Aveilla C, Oltean S, Harper SJ, Bates DO. The anti-angiogenic isoforms of VEGF in health and disease. Biochemical Society Transactions. 37: 1207-13. PMID 19909248 DOI: 10.1042/Bst0371207 |
0.485 |
|
| 2008 |
Oltean S, Febbo PG, Garcia-Blanco MA. Dunning rat prostate adenocarcinomas and alternative splicing reporters: powerful tools to study epithelial plasticity in prostate tumors in vivo. Clinical & Experimental Metastasis. 25: 611-9. PMID 18523850 DOI: 10.1007/S10585-008-9186-Y |
0.329 |
|
| 2007 |
Col B, Oltean S, Banerjee R. Translational regulation of human methionine synthase by upstream open reading frames. Biochimica Et Biophysica Acta. 1769: 532-40. PMID 17683808 DOI: 10.1016/J.Bbaexp.2007.06.003 |
0.5 |
|
| 2006 |
Bonano VI, Oltean S, Brazas RM, Garcia-Blanco MA. Imaging the alternative silencing of FGFR2 exon IIIb in vivo. Rna (New York, N.Y.). 12: 2073-9. PMID 17068207 DOI: 10.1261/Rna.248506 |
0.361 |
|
| 2006 |
Oltean S, Sorg BS, Albrecht T, Bonano VI, Brazas RM, Dewhirst MW, Garcia-Blanco MA. Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity. Proceedings of the National Academy of Sciences of the United States of America. 103: 14116-21. PMID 16963563 DOI: 10.1073/Pnas.0603090103 |
0.345 |
|
| 2005 |
Oltean S, Banerjee R. A B12-responsive internal ribosome entry site (IRES) element in human methionine synthase. The Journal of Biological Chemistry. 280: 32662-8. PMID 16051610 DOI: 10.1074/Jbc.M501964200 |
0.504 |
|
| 2003 |
Oltean S, Banerjee R. Nutritional modulation of gene expression and homocysteine utilization by vitamin B12. The Journal of Biological Chemistry. 278: 20778-84. PMID 12670934 DOI: 10.1074/Jbc.M300845200 |
0.49 |
|
| Show low-probability matches. |